Cargando…

Steroid-Refractory Acute GVHD: Predictors and Outcomes

Patients with steroid-resistant acute graft versus host disease (aGVHD) have a dismal prognosis, with mortality rates in excess of 90%. We sought to identify a subgroup of patients less likely to benefit from initial therapy with corticosteroids as well as the impact of response on day 14 on outcome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Westin, Jason R., Saliba, Rima M., De Lima, Marcos, Alousi, Amin, Hosing, Chitra, Qazilbash, Muzaffar H., Khouri, Issa F., Shpall, Elizabeth J., Anderlini, Paolo, Rondon, Gabriela, Andersson, Borje S., Champlin, Richard, Couriel, Daniel R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216266/ https://www.ncbi.nlm.nih.gov/pubmed/22110505 http://dx.doi.org/10.1155/2011/601953

Ejemplares similares

A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin’s lymphomas
por: Hosing, Chitra, et al.
Publicado: (2010)

Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement
por: Akin, Serkan, et al.
Publicado: (2022)

Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation
por: Saliba, Rima M., et al.
Publicado: (2020)

Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide
por: Mehta, Rohtesh S., et al.
Publicado: (2021)

Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies
por: Lekakis, L, et al.
Publicado: (2006)

A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study
por: Popat, Uday R., et al.
Publicado: (2022)

Allogeneic and Autologous Hematopoietic Transplants Can be Safely Performed after COVID-19 Infections
por: Ramdial, Jeremy L., et al.
Publicado: (2021)

Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant
por: Nieto, Yago, et al.
Publicado: (2023)

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
por: Popat, Uday R., et al.
Publicado: (2023)

P1270: MYELOABLATIVE FRACTIONATED BUSULFAN-BASED CONDITIONING REGIMEN IN PATIENTS WITH AML AND MDS: RESULTS OF A RANDOMIZED CLINICAL TRIAL COMPARING 2 FRACTIONATION SCHEDULES
por: Popat, Uday R., et al.
Publicado: (2023)

Allogeneic Hematopoietic Cell Transplantation for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
por: Bashir, Qaiser, et al.
Publicado: (2022)

Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients
por: Sheshadri, Ajay, et al.
Publicado: (2020)

Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes
por: Herzog, Shannon, et al.
Publicado: (2023)

Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis
por: Nieto, Yago, et al.
Publicado: (2021)

A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement
por: Mehta, Rohtesh S., et al.
Publicado: (2023)

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
por: Yeh, Jason, et al.
Publicado: (2021)

Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
por: Cheng, Yee Chung, et al.
Publicado: (2013)

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
por: Sobash, Philip T., et al.
Publicado: (2020)

Long-Term Follow-up Outcomes of Patients That Underwent Allogeneic or Autologous Hematopoietic Transplant Shortly after a COVID-19 Infection
por: Marinos, Alejandro, et al.
Publicado: (2023)

Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan
por: Nieto, Yago, et al.
Publicado: (2017)

Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy
por: Valdez, Benigno C., et al.
Publicado: (2016)

Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation
por: Cao, Kai, et al.
Publicado: (2018)

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation
por: Andersson, Borje S., et al.
Publicado: (2022)

Chronic Graft-Versus-Host Disease (cGVHD) Exacerbation after Sars-Cov-2 Covid Vaccination
por: Trunk, Andrew D., et al.
Publicado: (2021)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD
por: Zhang, Hongming, et al.
Publicado: (2015)

Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD
por: Baek, Dong Won, et al.
Publicado: (2022)

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
por: Liu, Yin, et al.
Publicado: (2022)

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium
por: DeFilipp, Zachariah, et al.
Publicado: (2021)

SIRPα Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies
por: Saliba, Rima M., et al.
Publicado: (2022)

A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept
por: Ostrin, Edwin J., et al.
Publicado: (2023)

Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases
por: Wernicke, Caroline M, et al.
Publicado: (2011)

2844. Butyrogenic Bacteria After Acute Graft vs. Host Disease Associate with the Development of Steroid Refractory GVHD
por: Golob, Jonathan L, et al.
Publicado: (2019)

Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies
por: Singh, Harjeet, et al.
Publicado: (2022)

Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials
por: Luo, Chengxin, et al.
Publicado: (2023)

Mesenchymal stem cell as salvage treatment for refractory chronic GVHD
por: Weng, J Y, et al.
Publicado: (2010)

Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy
por: Yang, Jingjing, et al.
Publicado: (2021)

Outcomes of Hospital-Associated Covid-19 in Hematopoietic Cell Transplant (HCT) Recipients: A Single Center Experience
por: Srinivasan, Krithika, et al.
Publicado: (2022)

P1303: DARATUMUMAB-BASED MAINTENANCE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AFTER SALVAGE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
por: Biavasco, Francesca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fp96iud0guc23jugfn6ae52qo4